Arbor Trust Wealth Advisors LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Arbor Trust Wealth Advisors LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 42.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,886 shares of the company’s stock after purchasing an additional 559 shares during the period. Arbor Trust Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,456,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. SeaTown Holdings Pte. Ltd. increased its stake in shares of Eli Lilly and Company by 34.5% in the fourth quarter. SeaTown Holdings Pte. Ltd. now owns 12,348 shares of the company’s stock worth $9,533,000 after purchasing an additional 3,170 shares in the last quarter. Perkins Coie Trust Co increased its stake in shares of Eli Lilly and Company by 2.3% in the fourth quarter. Perkins Coie Trust Co now owns 6,050 shares of the company’s stock worth $4,671,000 after purchasing an additional 136 shares in the last quarter. Clarius Group LLC increased its stake in shares of Eli Lilly and Company by 31.2% in the fourth quarter. Clarius Group LLC now owns 7,920 shares of the company’s stock worth $6,114,000 after purchasing an additional 1,884 shares in the last quarter. Oak Ridge Investments LLC increased its stake in shares of Eli Lilly and Company by 6.2% in the fourth quarter. Oak Ridge Investments LLC now owns 55,243 shares of the company’s stock worth $42,648,000 after purchasing an additional 3,201 shares in the last quarter. Finally, J2 Capital Management Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $357,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 4.1 %

Shares of NYSE LLY opened at $726.24 on Tuesday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52 week low of $612.70 and a 52 week high of $972.53. The firm’s fifty day moving average is $781.14 and its 200 day moving average is $854.04. The company has a market cap of $689.43 billion, a price-to-earnings ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. During the same period in the previous year, the firm earned $0.10 earnings per share. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post 13.14 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.83%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s payout ratio is presently 56.22%.

Eli Lilly and Company declared that its Board of Directors has initiated a share buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Citigroup raised their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective for the company. Finally, StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, January 1st. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,002.22.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the business’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.13% of the stock is owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.